<DOC>
	<DOCNO>NCT01682135</DOCNO>
	<brief_summary>This trial test ramucirumab ( LY3009806 ) administer Chinese participant advance solid tumor resistant standard therapy standard therapy available . The purpose study evaluate safe ramucirumab whether cause side effect . The study also measure much ramucirumab get blood stream long take body get rid .</brief_summary>
	<brief_title>A Study Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Chinese participant histopathologically cytologically diagnose advanced solid tumor Did respond standard therapy standard therapy available Measurable nonmeasurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) Eastern Cooperative Oncology Group ( ECOG ) performance status score 01 study entry Able provide write informed consent A life expectancy &gt; 3 month Adequate hematologic function , define : Absolute neutrophil count ( ANC ) ≥1500 per cubic millimeter ( mm^3 ) ; hemoglobin concentration ≥9 gram per deciliter ( g/dL ) ; platelet count ≥100,000/mm^3 Adequate hepatic function , define : Total bilirubin level ≤1.5 x upper limit normal ( ULN ) ( participant know Gilbert Syndrome , total bilirubin ≤ 3.0 x ULN direct bilirubin ≤ 1.5 x ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 x ULN ( ≤5 x ULN participant liver metastasis Adequate renal function , define : Serum creatinine level ≤1.5 x ULN ; calculate serum creatinine clearance ( CockcroftGault ) ≥50 milliliter per minute ( mL/min ) Urinary protein 0 1+ dipstick edema serum albumin &lt; low level normal Adequate coagulation function , define : International normalized ratio ( INR ) ≤1.5 , prothrombin time ( PT ) ≤1.5 x ULN activate partial thromboplastin time ( aPTT ) ≤1.5 x ULN ( unless receive anticoagulation therapy ) Agrees use adequate contraception study period 12 week last dose study treatment Had chemotherapy therapeutic radiotherapy within 14 day ( 6 week nitrosoureas mitomycin C ) enter study participant ongoing side effect ( ≥ Grade 2 ) due previously administer agent Has obvious evidence intratumor cavitation Has undergone major surgery within 28 day study entry central venous access device insert within 7 day study entry Has history gastrointestinal perforation , postoperative bleeding complication , wound complication surgical procedure Has elective plan surgery conduct trial Has document and/or symptomatic brain leptomeningeal metastasis Has uncontrolled ongoing illness , example : thrombotic hemorrhagic disorder ; hemoptysis ; ongoing infection require systemic antibiotic treatment ; congestive heart failure , angina pectoris , angioplasty , stenting , myocardial infarction within 6 month ; stroke , transient ischemic attack ( TIA ) , grade 34 arterial thromboembolic event occur within 6 month ; uncontrolled hypertension ( ≥150/≥90 millimeter mercury [ mmHg ] ) ; cardiac arrhythmia require treatment asymptomatic sustain ventricular tachycardia ; peripheral neuropathy ≥Grade 2 ; human immunodeficiency virus ( HIV ) active , uncontrolled hepatitis , liver cirrhosis level ChildPugh Class B ( bad ) , liver cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis . ( Clinically meaningful ascites define ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis ) Has serious nonhealing wound , ulcer , bone fracture within 28 day study entry Has experience Grade 3 4 gastrointestinal bleeding within 3 month study entry Has history abdominal fistula , gastrointestinal perforation , intraabdominal abscess &lt; 6 month randomization , participant history poorly control recurrent inflammatory bowel disease ( include Crohn 's disease ulcerative colitis ) Has participate clinical study nonapproved experimental agent procedure within 4 week prior study entry small molecule , 8 week study entry nonapproved monoclonal antibody Has know allergy ramucirumab excipients , monoclonal antibody ( MAb ) , therapeutic protein , fresh frozen plasma , human serum albumin ( HSA ) , cytokine , interleukin . If suspicion participant may allergy , participant exclude Is pregnant ( confirmed urine serum pregnancy test ) lactating Has know alcohol drug dependency Is receive chronic therapy nonsteroidal antiinflammatory agent ( NSAIDs ) Is consider suitable study , opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>